Based on these results, it is possible to speculate that the combination of AIM2 inflammasome modulators, as in the case of thalidomide, with conventional chemotherapeutic drugs or immunotherapies could improve the anti-tumor effects in patients with advanced cancer, including those who develop chemotherapy resistance or undergo metastatic disease. This evidence concerns the gene AIM2 and neoplasm.